CMD-193

DRUG3 trials

Sponsors

Wyeth is now a wholly owned subsidiary of Pfizer, Ludwig Institute for Cancer Research

Conditions

Neoplasms

Phase 1

Study Evaluating CMD-193 in Advanced Malignant Solid Tumors

CompletedNCT00161642

Wyeth is now a wholly owned subsidiary of PfizerNeoplasms

Start: 2004-11-30End: 2007-07-31Updated: 2009-09-10

Study Evaluating Intravenous CMD-193 in Subjects With Advanced Malignant Solid Tumors

TerminatedNCT00257881

Wyeth is now a wholly owned subsidiary of PfizerNeoplasms

Start: 2005-11-30End: 2006-12-31Target: 46Updated: 2007-12-10

Biodistribution Study of CMD-193 in Patients With Advanced Tumours Expressing the Lewis-Y Antigen

TerminatedNCT00293215

Ludwig Institute for Cancer ResearchNeoplasms

Start: 2006-02-28End: 2007-05-31Updated: 2022-10-10